Neuropsychiatric side effects of efavirenz therapy

Expert Opinion on Drug Safety

Volumn 6, Issue 2, 2007, Pages 147-154

  Arendt, Gabriele ^a   de Nocker, Dominique ^a   von Giesen, Hans Juergen ^b   Nolting, Thorsten ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b Alexian Hospital   (Germany)

Author keywords

Drug safety; Efavirenz; HIV infection; Neuropsychiatric side effects

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; AZITHROMYCIN; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; CYTOKINE ANTIBODY; CYTOKINE RECEPTOR ANTAGONIST; EFAVIRENZ; ETHINYLESTRADIOL; FLUOXETINE; FLUVOXAMINE; INDINAVIR; INTERLEUKIN 1BETA; INTERLEUKIN 6; LYSERGIDE; METHADONE; MIDAZOLAM; NEVIRAPINE; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; SEROTONIN UPTAKE INHIBITOR; TENOFOVIR; TRIAZOLAM; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PSYCHOSIS; AFFECT; AMNESIA; ANXIETY; BRAIN DAMAGE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CONCENTRATION LOSS; CONCENTRATION RESPONSE; DEPERSONALIZATION; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DEPENDENCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; FATIGUE; GUILT; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INSOMNIA; IRRITABILITY; LIVER DISEASE; MAINTENANCE THERAPY; MENTAL DISEASE; NEUROTOXICITY; NIGHTMARE; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PARANOIA; PATIENT COMPLIANCE; PERSONALITY DISORDER; REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; SUICIDAL IDEATION; THOUGHT DISORDER; VIRUS LOAD; VIRUS RESISTANCE; WORK DISABILITY;

HUMANS; MENTAL DISORDERS; NEUROPSYCHOLOGICAL TESTS; NEVIRAPINE; OXAZINES;

EID: 33847757854     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.6.2.147     Document Type: Review

References (48)

1. BARY M, DAVID F, GASNAULT J et al.: Neurospychiatric symptoms in HIV infected patients and the role of efavirenz. Med. Mal. Inject. (2004) 34(10):435-449.
2. DAWSON S, WOODS C: Neuro-psychiatric effects of efavirenz: delayed onset. Int. J. STD AIDS (2005) 16(11):769-770.
3. VON GIESEN H-J, HEFTER H, THEISEN A, KOLLER H, ARENDT G: Therapeutic effects of HIV-1 NNRTI on the central nervous system. J. Acquir. Immune Defic. Syndr. (2002) 29(4):363-367.
4. YOUNG SD, BRITCHER SF, TRAN LO et al.: L-743 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. (1995) 39(12):2602-2605.
5. MA Q, OKUSANYA OO, SMITH PF et al.: Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert Opin. Drug Metab. Toxicol. (2005) 1(3):473-485.
6. FORTIN C, JOLY V: Efavirenz for HIV-1 infection in adult: an overview. Expert Rev. Anti Infect. Ther. (2004) 2(5):671-684. Review on EFV efficacy, pharmacokinetics and safety.
7. BLANCH J, MARTINEZ E, ROUSAUD A et al.: Preliminary data of a prospective study on neuro-psychiatric side effects after initiation of efavirenz. J. Acquir. Immune Defic. Syndr. (2001) 27(4):336-343.
8. VON GIESEN H-J, KOELLER H, DE NOCKER D, HASLINGER B, ARENDT G: Long-term safety and efficacy of NNRTI within the central nervous system. HIV Clin. Trials (2003) 4(6):382-390.
9. LOCHET P, PEYRIERE H, LOTTHE A, MAUBOUSSIN JM, DELMAS B, REYNES J: Long-term assessment of neuro-psychiatric adverse reactions associated with efavirenz. HIV Med. (2003) 4(1):62-66.
10. HAWKINS T, GEIST C, YOUNG B et al.: Comparison of neuro-psychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clin. Trials (2005) 6(4):187-196.
11. PEREZ-MOLINA JA: Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1033 HIV-infected patients. HIV Clin. Trials (2002) 3(4):279-286.
12. MANFREDI R, CALZA L, CHIODO F: Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. J. Acquir. Immune Defic. Syndr. (2004) 35(5):492-502.
13. GALLEGO L, BARREIRO P, DEL RIO R et al.: Analyzing sleep abnormalities in HIV-infected patients treated with efavirenz. Clin. Infect. Dis. (2004) 38(3):430-432.
14. MOYLE G, FLETCHER C, BROWN H, MANDALIA S, GAZZARD B: Changes in sleep quality and brain wave patterns following initiation of an efavirenz-containing triple antiretroviral regimen. HIV Med (2006) 7(4):243-247.
15. JUETHNER SN, SEYFRIED W, ABERG JA: Tolerance of efavirenz-induced central nervous system side effects in HIV-infected individuals with a history of substance abuse. HIV Clin. Trials (2003) 4(3):145-149.
16. VAZQUEZ E: Sustiva flashbacks. Posit. Aware (1999) 10(2):17.
17. FAGGIAN F, LATTUADA E, LANZAFAME M, ANTOLINI D, CONCIA E, VENTO S: Recreational substance use and tolerance of efavirenz in HIV-1 infected patients. AIDS Care (2005) 17(7):908-910.
18. CLARKE SM, MULCAHY FM, TIJA J et al.: The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br. J. Clin. Pharmacol. (2001) 51:213.
19. CLIFFORD DB, EVANS S, YANG Y et al.: Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann. Intern. Med. (2005) 143(10):714-721. Summary for patients in: Ann. Intern. Med. (2005) 143(10):I43.
20. SPIRE B, CARRIERI P, GARZOT MA, UHENHAFF M, OBADIA Y; TRT 5 Group: Factors associated with efavirenz discontinuation in a large community based sample of patients. AIDS Care (2004) 16(5):558-564.
21. PEYRIERE H, MAUBOUSSIN JM, ROUANET I, FABRE J, REYNES J, HILLAIRE-BUYS D: Management of sudden psychiatric disorders related to efavirenz. AIDS (2001) 15(10):1323-1324.
22. PUZANTIAN T: Central nervous system adverse effects with efavirenz: case report and review. Pharmacotherapy (2002) 22(7):930-933.
23. WELCH KJ, MORSE A: Association between efavirenz and selected psychiatric and neurological conditions. J. Infect. Dis. (2002) 185(2):268-269.
24. FUMAZ CR, MUNOZ-MORENO JA, MOLTO J et al.: Long-term neuro-psychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J. Acquir. Immune Defic. Syndr. (2005) 38(5):560-565.
25. O'MAHONY SM, MYINT AM, STEINBUSCH H, LEONARD BE: Efavirenz induces depressive-like behaviour, increased stress response and changes in the immune response in rats. Neuroimmunomodulation (2005) 12(5):293-298.
26. BOLY L, CAFARO V, DYNER T: Depressive symptoms predict increased incidence of neuro-psychiatric side effects in patients treated with efavirenz. J. Acquir. Immune Defic. Syndr. (2006) 42(4):514-515.
27. LANG JP, HALLEGUEN O, PICARD A, LANG JM, DANION JM: Apropos of atypical melancholia with Sustiva (efavirenz). Encéphale (2001) 27(3):290-293.
28. MORENO A, LABELLE C, SAMET JH: Recurrence of post-traumatic stress disorder symptoms after initiation of antiretrovirals including efavirenz: a report of two cases. HIV Med. (2003) 4(3):302-304.
29. JOURNOT V, CHENE G, DE CASTRO N et al.; ALIZE STUDY GROUP: Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099. Clin. Inject. Dis. (2006) 42(12):1790-1799.
30. WARD DJ, CURTIN JM: Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuro-psychiatric adverse events and improvement in lipid profiles. AIDS Patient Care STDS. (2006) 20(8):542-548.
31. ALLAVENA C, LE MOAL G, MICHAU C, CHIFFOLEAU A, RAFFI F: Neuro-psychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: a report of nine cases. Antivir. Ther. (2006) 11(2):263-265.
32. COLLAZOS J, IBARRA S, LOUREIRO M: Cortisol serum levels and their relationship to certain antiretroviral drugs. Scand. J. Infect. Dis. (2004) 36(6-7):480-482.
33. STAHLE L, MOBERG L, SVENSSON JO, SONNERBORG A: Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. Ther. Drug Monit. (2004) 26(3):267-270.
34. MARZOLINI C, TELENTI A, DECOSTERD LA, GREUB G, BIOLLAZ J, BUCLIN T: Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS (2001) 15(1):71-75.
35. GUTIERREZ F, NAVARRO A, PADILLA S et al.: Prediction of neuro-psychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin. Infect. Dis. (2005) 41(11):1648-1653.
36. KAPPELHOFF BS, VAN LETH F, ROBINSON PA et al.; 2NN STUDY GROUP: Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir. Ther. (2005) 10(4):489-498.
37. LETH FV, KAPPELHOFF BS, JOHNSON D et al.; 2NN STUDY GROUP: Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. AIDS Res. Hum. Retroviruses (2006) 22(3):232-239.
38. LETH FV, ANDREWS S, GRINSZTEJN B et al.; 2NN STUDY GROUP: The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS (2005) 19(5):463-471.
39. BICKEL M, STEPHAN C, ROTTMANN C et al.: Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis. Scand. J. Infect. Dis. (2005) 37(6-7):520-522.
40. ROTGER M, COLOMBO S, FURRER H et al.; SWISS HIV COHORT STUDY: Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet. Genomics (2005) 15(1):1-5.
41. HASSE B, GUNTHARD HF, BLEIBER G, KRAUSE M: Efavirenz intoxication due to slow hepatic metabolism. Clin. Infect. Dis. (2005) 40(3):e22-e23.
42. HAAS DW, RIBAUDO HJ, KIM RB et al.: Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group Study. AIDS (2004) 18(18):2391-2400.
43. CSAJKA C, MARZOLINI C, FATTINGER K et al.: Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin. Pharmacol. Ther. (2003) 73(1):20-30.
44. TUAILLON E, GUEUDIN M, LEMEE V et al.: Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. J. Acquir. Immune Defic. Syndr. (2004) 37(5):1543-1549.
45. DEMETER LM, RIBAUDO HJ, ERICE A et al.; AIDS CLINICAL TRIAL GROUP PROTOCOL 388: HIV drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trial Group Protocol 388. Clin. Infect. Dis. (2004) 39(4):552-558.
46. DEL RIO C: Top stories of 2004. ACTG 5095: efavirenz beats AZT + 3TC + abacavir. AIDS Clin. Care (2005) 17(1):4.
47. MOULY S, LOWN KS, KORNHAUSER D et al.: Hepatic, but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin. Pharmacol. Ther. (2002) 72(1):1-9.
48. BARRETT JS, JOSHI AS, CHAI M, LUDDEN TM, FISKE WD, PIENIASZEK HJ Jr: Population pharmacokinetic meta-analysis with efavirenz. Int. J. Clin. Pharamacol. Ther. (2002) 40(11):507-519.